Scolaris Content Display Scolaris Content Display

Related content

Jump to:

Related reviews and protocols

Topics

Topics

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dl) at cycle 3.
Figures and Tables -
Analysis 1.1

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dl) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 2 Fasting serum insulin (µU/ml) at cycle 3.
Figures and Tables -
Analysis 1.2

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 2 Fasting serum insulin (µU/ml) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 3 Glucose AUC (h x mg/dl) at cycle 3.
Figures and Tables -
Analysis 1.3

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 3 Glucose AUC (h x mg/dl) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 4 Insulin AUC (h x µU/ml) at cycle 3.
Figures and Tables -
Analysis 1.4

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 4 Insulin AUC (h x µU/ml) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 5 Change in fasting glycosylated hemoglobin (%) at cycle 3.
Figures and Tables -
Analysis 1.5

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 5 Change in fasting glycosylated hemoglobin (%) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 6 Fasting blood glucose (mmol/L) at cycle 6.
Figures and Tables -
Analysis 1.6

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 6 Fasting blood glucose (mmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 7 Fasting blood insulin (µU/ml) at cycle 6.
Figures and Tables -
Analysis 1.7

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 7 Fasting blood insulin (µU/ml) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 8 Change in insulin AUC (µU/mL) by 6 months.
Figures and Tables -
Analysis 1.8

Comparison 1 Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg, Outcome 8 Change in insulin AUC (µU/mL) by 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dl) at cycle 3.
Figures and Tables -
Analysis 2.1

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dl) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Fasting serum insulin (µU/ml) at cycle 3.
Figures and Tables -
Analysis 2.2

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Fasting serum insulin (µU/ml) at cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Glucose AUC (h x mg/dl) in cycle 3.
Figures and Tables -
Analysis 2.3

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Glucose AUC (h x mg/dl) in cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 4 Insulin AUC (h x µU/ml) in cycle 3.
Figures and Tables -
Analysis 2.4

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 4 Insulin AUC (h x µU/ml) in cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 5 Change in fasting glycosylated hemoglobin (%) in cycle 3.
Figures and Tables -
Analysis 2.5

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 5 Change in fasting glycosylated hemoglobin (%) in cycle 3.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 6 Fasting blood glucose (mmol/l) at cycle 6.
Figures and Tables -
Analysis 2.6

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 6 Fasting blood glucose (mmol/l) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 7 Fasting blood glucose (mmol/l) at cycle 12.
Figures and Tables -
Analysis 2.7

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 7 Fasting blood glucose (mmol/l) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 8 Fasting blood glucose (mmol/l) at cycle 24.
Figures and Tables -
Analysis 2.8

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 8 Fasting blood glucose (mmol/l) at cycle 24.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 9 Glucose 2‐h response (mmol/l) at cycle 6.
Figures and Tables -
Analysis 2.9

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 9 Glucose 2‐h response (mmol/l) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 10 Glucose 2‐h response (mmol/l) at cycle 12.
Figures and Tables -
Analysis 2.10

Comparison 2 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 10 Glucose 2‐h response (mmol/l) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 1 Fasting blood glucose (mmol/L) at cycle 6.
Figures and Tables -
Analysis 3.1

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 1 Fasting blood glucose (mmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 2 Fasting blood insulin (mlU/L) at cycle 6.
Figures and Tables -
Analysis 3.2

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 2 Fasting blood insulin (mlU/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 3 Fasting C‐peptide (pmol/L) at cycle 6.
Figures and Tables -
Analysis 3.3

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 3 Fasting C‐peptide (pmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 4 Glucose AUC (min x mmol/L) at cycle 6.
Figures and Tables -
Analysis 3.4

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 4 Glucose AUC (min x mmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 5 Insulin AUC (min x mlU/L) at cycle 6.
Figures and Tables -
Analysis 3.5

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 5 Insulin AUC (min x mlU/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 6 C‐peptide AUC (min x nmol/L) at cycle 6.
Figures and Tables -
Analysis 3.6

Comparison 3 Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg, Outcome 6 C‐peptide AUC (min x nmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 1 Fasting plasma glucose (mg/dL) after 6 cycles.
Figures and Tables -
Analysis 4.1

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 1 Fasting plasma glucose (mg/dL) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 2 Fasting plasma insulin (µU/ml) after 6 cycles.
Figures and Tables -
Analysis 4.2

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 2 Fasting plasma insulin (µU/ml) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 3 Fasting plasma insulin (mIU/ml) after 6 cycles.
Figures and Tables -
Analysis 4.3

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 3 Fasting plasma insulin (mIU/ml) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 4 Fasting C‐peptide (pmol/L) after 6 cycles.
Figures and Tables -
Analysis 4.4

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 4 Fasting C‐peptide (pmol/L) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 5 Glucose AUC (h x g/L) after 6 cycles.
Figures and Tables -
Analysis 4.5

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 5 Glucose AUC (h x g/L) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 6 Insulin AUC (h x IU/ml) after 6 cycles.
Figures and Tables -
Analysis 4.6

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 6 Insulin AUC (h x IU/ml) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 7 C‐peptide AUC (h x pmol/L) after 6 cycles.
Figures and Tables -
Analysis 4.7

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 7 C‐peptide AUC (h x pmol/L) after 6 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 8 Fasting glucose (g/L) after 13 cycles.
Figures and Tables -
Analysis 4.8

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 8 Fasting glucose (g/L) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 9 Fasting insulin (IU/ml) after 13 cycles.
Figures and Tables -
Analysis 4.9

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 9 Fasting insulin (IU/ml) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 10 Fasting C‐peptide (pmol/L) after 13 cycles.
Figures and Tables -
Analysis 4.10

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 10 Fasting C‐peptide (pmol/L) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 11 Glucose AUC (h x g/L) after 13 cycles.
Figures and Tables -
Analysis 4.11

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 11 Glucose AUC (h x g/L) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 12 Insulin AUC (h x IU/ml) after 13 cycles.
Figures and Tables -
Analysis 4.12

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 12 Insulin AUC (h x IU/ml) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 13 C‐peptide AUC (h x pmol/L) after 13 cycles.
Figures and Tables -
Analysis 4.13

Comparison 4 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg, Outcome 13 C‐peptide AUC (h x pmol/L) after 13 cycles.

Navigate to figure in ReviewOpen in new tab

Comparison 5 Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg, Outcome 1 Fasting plasma glucose (mg/dL) after cycle 6.
Figures and Tables -
Analysis 5.1

Comparison 5 Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg, Outcome 1 Fasting plasma glucose (mg/dL) after cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 5 Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg, Outcome 2 Fasting plasma insulin (mIU/mL) after cycle 6.
Figures and Tables -
Analysis 5.2

Comparison 5 Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg, Outcome 2 Fasting plasma insulin (mIU/mL) after cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 6 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg, Outcome 1 Fasting plasma glucose (mg/dL) after cycle 6.
Figures and Tables -
Analysis 6.1

Comparison 6 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg, Outcome 1 Fasting plasma glucose (mg/dL) after cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 6 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg, Outcome 2 Fasting plasma insulin (mIU/mL) after cycle 6.
Figures and Tables -
Analysis 6.2

Comparison 6 Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg, Outcome 2 Fasting plasma insulin (mIU/mL) after cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 7 Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.
Figures and Tables -
Analysis 7.1

Comparison 7 Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 7 Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg, Outcome 2 Insulin AUC at 6 months.
Figures and Tables -
Analysis 7.2

Comparison 7 Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg, Outcome 2 Insulin AUC at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 1 Glucose AUC (mmol/L) at 6 months.
Figures and Tables -
Analysis 8.1

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 1 Glucose AUC (mmol/L) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 2 Insulin AUC (pmol/L) at 6 months.
Figures and Tables -
Analysis 8.2

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 2 Insulin AUC (pmol/L) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 3 C‐peptide AUC (pmol/L) at 6 months.
Figures and Tables -
Analysis 8.3

Comparison 8 Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg, Outcome 3 C‐peptide AUC (pmol/L) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.
Figures and Tables -
Analysis 9.1

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Insulin AUC at 6 months.
Figures and Tables -
Analysis 9.2

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Insulin AUC at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting blood glucose (mmol/l) at cycle 6.
Figures and Tables -
Analysis 9.3

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting blood glucose (mmol/l) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Fasting blood glucose (mmol/l) at cycle 12.
Figures and Tables -
Analysis 9.4

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Fasting blood glucose (mmol/l) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 5 Glucose 2‐h response (mmol/l) at cycle 6.
Figures and Tables -
Analysis 9.5

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 5 Glucose 2‐h response (mmol/l) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 6 Glucose 2‐h response (mmol/l) at cycle 12.
Figures and Tables -
Analysis 9.6

Comparison 9 Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 6 Glucose 2‐h response (mmol/l) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 10 Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.
Figures and Tables -
Analysis 10.1

Comparison 10 Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Glucose AUC (mg/dl) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 10 Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Insulin AUC at 6 months.
Figures and Tables -
Analysis 10.2

Comparison 10 Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Insulin AUC at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 11 Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Change in glucose (mg/dL) from fasting to 1 h after 400 kcal drink at cycle 6.
Figures and Tables -
Analysis 11.1

Comparison 11 Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Change in glucose (mg/dL) from fasting to 1 h after 400 kcal drink at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 11 Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Change in insulin (µU/ml) from fasting to 1 h after 400 kcal drink at cycle 6.
Figures and Tables -
Analysis 11.2

Comparison 11 Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Change in insulin (µU/ml) from fasting to 1 h after 400 kcal drink at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 1 Change in glucose AUC (mg/dL) by 6 months.
Figures and Tables -
Analysis 12.1

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 1 Change in glucose AUC (mg/dL) by 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 2 Change in insulin AUC (µU/mL) by 6 months.
Figures and Tables -
Analysis 12.2

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 2 Change in insulin AUC (µU/mL) by 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 3 Change in C‐peptide AUC (ng/mL) by 6 months.
Figures and Tables -
Analysis 12.3

Comparison 12 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg), Outcome 3 Change in C‐peptide AUC (ng/mL) by 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Glucose AUC (hr x mmol/L) at cycle 6.
Figures and Tables -
Analysis 13.1

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Glucose AUC (hr x mmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Insulin AUC (hr x pmol/L) at cycle 6.
Figures and Tables -
Analysis 13.2

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Insulin AUC (hr x pmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Fasting glycosylated hemoglobin (%) at cycle 6.
Figures and Tables -
Analysis 13.3

Comparison 13 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Fasting glycosylated hemoglobin (%) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 14 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg, Outcome 1 Impaired glucose tolerance at cycle 5.
Figures and Tables -
Analysis 14.1

Comparison 14 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg, Outcome 1 Impaired glucose tolerance at cycle 5.

Navigate to figure in ReviewOpen in new tab

Comparison 14 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg, Outcome 2 Insulin sensitivity at cycle 5.
Figures and Tables -
Analysis 14.2

Comparison 14 Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg, Outcome 2 Insulin sensitivity at cycle 5.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 1 Fasting plasma glucose (mmol/L) at 12 months.
Figures and Tables -
Analysis 15.1

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 1 Fasting plasma glucose (mmol/L) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 2 Fasting plasma glucose at 24 months.
Figures and Tables -
Analysis 15.2

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 2 Fasting plasma glucose at 24 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 3 Fasting plasma insulin (pmol/L) at 12 months.
Figures and Tables -
Analysis 15.3

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 3 Fasting plasma insulin (pmol/L) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 4 Fasting plasma insulin (pmol/L) at 24 months.
Figures and Tables -
Analysis 15.4

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 4 Fasting plasma insulin (pmol/L) at 24 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 5 Fasting glycosylated hemoglobin (%) at 12 months.
Figures and Tables -
Analysis 15.5

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 5 Fasting glycosylated hemoglobin (%) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 6 Fasting glycosylated hemoglobin (%) at 24 months.
Figures and Tables -
Analysis 15.6

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 6 Fasting glycosylated hemoglobin (%) at 24 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 7 Glucose incremental AUC (min x mmol/L) at 12 months.
Figures and Tables -
Analysis 15.7

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 7 Glucose incremental AUC (min x mmol/L) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 8 Glucose incremental AUC (min x mmol/L) at 24 months.
Figures and Tables -
Analysis 15.8

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 8 Glucose incremental AUC (min x mmol/L) at 24 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 9 Insulin incremental AUC (min x nmol/L) at 12 months.
Figures and Tables -
Analysis 15.9

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 9 Insulin incremental AUC (min x nmol/L) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 10 Insulin incremental AUC (min x nmol/L) at 24 months.
Figures and Tables -
Analysis 15.10

Comparison 15 Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant), Outcome 10 Insulin incremental AUC (min x nmol/L) at 24 months.

Navigate to figure in ReviewOpen in new tab

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 1 Change in fasting blood insulin (mU/L) at cycle 7.
Figures and Tables -
Analysis 16.1

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 1 Change in fasting blood insulin (mU/L) at cycle 7.

Navigate to figure in ReviewOpen in new tab

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 2 Change in glucose AUC (h x mg/L) at cycle 7.
Figures and Tables -
Analysis 16.2

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 2 Change in glucose AUC (h x mg/L) at cycle 7.

Navigate to figure in ReviewOpen in new tab

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 3 Change in fasting C‐peptide (ng/mL) at cycle 7.
Figures and Tables -
Analysis 16.3

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 3 Change in fasting C‐peptide (ng/mL) at cycle 7.

Navigate to figure in ReviewOpen in new tab

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 4 Change in C‐peptide 2‐h response (ng/mL) at cycle 7.
Figures and Tables -
Analysis 16.4

Comparison 16 Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg, Outcome 4 Change in C‐peptide 2‐h response (ng/mL) at cycle 7.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 1 Change in fasting plasma glucose (mg/dL) by cycle 13.
Figures and Tables -
Analysis 17.1

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 1 Change in fasting plasma glucose (mg/dL) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 2 Change in fasting plasma insulin (µU/mL) by cycle 13.
Figures and Tables -
Analysis 17.2

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 2 Change in fasting plasma insulin (µU/mL) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 3 Change in fasting C‐peptide (µmol/L) by cycle 13.
Figures and Tables -
Analysis 17.3

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 3 Change in fasting C‐peptide (µmol/L) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 4 Change in fasting free fatty acids (µEq/L) by cycle 13.
Figures and Tables -
Analysis 17.4

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 4 Change in fasting free fatty acids (µEq/L) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 5 Change in glucose AUC (h x mg/dL) by cycle 13.
Figures and Tables -
Analysis 17.5

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 5 Change in glucose AUC (h x mg/dL) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 6 Change in insulin AUC (h x µU/mL) by cycle 13.
Figures and Tables -
Analysis 17.6

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 6 Change in insulin AUC (h x µU/mL) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 7 Change in C‐peptide AUC (h x µmol/L) by cycle 13.
Figures and Tables -
Analysis 17.7

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 7 Change in C‐peptide AUC (h x µmol/L) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 8 Change in free fatty acids AUC (h x µEq/L) by cycle 13.
Figures and Tables -
Analysis 17.8

Comparison 17 Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg, Outcome 8 Change in free fatty acids AUC (h x µEq/L) by cycle 13.

Navigate to figure in ReviewOpen in new tab

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dL) at 12 months.
Figures and Tables -
Analysis 18.1

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Fasting serum glucose (mg/dL) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Change in fasting blood glucose (mg/dL) at 12 months.
Figures and Tables -
Analysis 18.2

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 2 Change in fasting blood glucose (mg/dL) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Glucose 2‐h response (mg/dL) at 12 months.
Figures and Tables -
Analysis 18.3

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 3 Glucose 2‐h response (mg/dL) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 4 Change in glucose 2‐h response (mg/dL) at 12 months.
Figures and Tables -
Analysis 18.4

Comparison 18 Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 4 Change in glucose 2‐h response (mg/dL) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 1 Fasting plasma glucose (mmol/L) at 6 months.
Figures and Tables -
Analysis 19.1

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 1 Fasting plasma glucose (mmol/L) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 2 Fasting glycosylated hemoglobin (%) at 6 months.
Figures and Tables -
Analysis 19.2

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 2 Fasting glycosylated hemoglobin (%) at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 3 Abnormal fasting plasma glucose at 6 months.
Figures and Tables -
Analysis 19.3

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 3 Abnormal fasting plasma glucose at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 4 Abnormal fasting glycosylated hemoglobin at 6 months.
Figures and Tables -
Analysis 19.4

Comparison 19 Norethisterone 350 µg versus levonorgestrel 30 µg, Outcome 4 Abnormal fasting glycosylated hemoglobin at 6 months.

Navigate to figure in ReviewOpen in new tab

Comparison 20 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 100 µg + EE 20 µg, Outcome 1 Change in glucose (mmol/L) from baseline to cycle 4.
Figures and Tables -
Analysis 20.1

Comparison 20 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 100 µg + EE 20 µg, Outcome 1 Change in glucose (mmol/L) from baseline to cycle 4.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.
Figures and Tables -
Analysis 21.1

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Fasting plasma glucose (mg/dl) at cycle 12.
Figures and Tables -
Analysis 21.2

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Fasting plasma glucose (mg/dl) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting plasma insulin (µg/dl) at cycle 6.
Figures and Tables -
Analysis 21.3

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting plasma insulin (µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Fasting plasma insulin (µU/ml) at cycle 6.
Figures and Tables -
Analysis 21.4

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Fasting plasma insulin (µU/ml) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 5 Fasting plasma insulin (µU/ml) at cycle 12.
Figures and Tables -
Analysis 21.5

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 5 Fasting plasma insulin (µU/ml) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 6 Glucose AUC (h x mg/dl) at cycle 6.
Figures and Tables -
Analysis 21.6

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 6 Glucose AUC (h x mg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 7 Glucose AUC (h x mg/dl) at cycle 12.
Figures and Tables -
Analysis 21.7

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 7 Glucose AUC (h x mg/dl) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 8 Insulin AUC (h x µg/dl) at cycle 6.
Figures and Tables -
Analysis 21.8

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 8 Insulin AUC (h x µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 9 Insulin AUC (h x µU/mL) at cycle 6.
Figures and Tables -
Analysis 21.9

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 9 Insulin AUC (h x µU/mL) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 10 Insulin AUC (h x µU/mL) at cycle 12.
Figures and Tables -
Analysis 21.10

Comparison 21 Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 10 Insulin AUC (h x µU/mL) at cycle 12.

Navigate to figure in ReviewOpen in new tab

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.
Figures and Tables -
Analysis 22.1

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Glucose AUC (h x µg/dl) at cycle 6.
Figures and Tables -
Analysis 22.2

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Glucose AUC (h x µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting plasma insulin (µg/dl) at cycle 6.
Figures and Tables -
Analysis 22.3

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 3 Fasting plasma insulin (µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Insulin AUC (h x µg/dl) at cycle 6.
Figures and Tables -
Analysis 22.4

Comparison 22 Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 4 Insulin AUC (h x µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.
Figures and Tables -
Analysis 23.1

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 2 Fasting plasma insulin (µg/dl) at cycle 6.
Figures and Tables -
Analysis 23.2

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 2 Fasting plasma insulin (µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 3 Glucose AUC (h x µg/dl) at cycle 6.
Figures and Tables -
Analysis 23.3

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 3 Glucose AUC (h x µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 4 Insulin AUC (h x µg/dl) at cycle 6.
Figures and Tables -
Analysis 23.4

Comparison 23 Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg, Outcome 4 Insulin AUC (h x µg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 1 Fasting serum glucose (mg/dl) after 12 months.
Figures and Tables -
Analysis 24.1

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 1 Fasting serum glucose (mg/dl) after 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 2 Glucose 2‐hr response (mg/dl) after 12 months.
Figures and Tables -
Analysis 24.2

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 2 Glucose 2‐hr response (mg/dl) after 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 3 Fasting serum insulin (nU/ml) after 12 months.
Figures and Tables -
Analysis 24.3

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 3 Fasting serum insulin (nU/ml) after 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 4 Insulin 2‐hr response (nU/ml) after 12 months.
Figures and Tables -
Analysis 24.4

Comparison 24 Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg, Outcome 4 Insulin 2‐hr response (nU/ml) after 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.
Figures and Tables -
Analysis 25.1

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 1 Fasting plasma glucose (mg/dl) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 2 Fasting plasma insulin (µU/ml) at cycle 6.
Figures and Tables -
Analysis 25.2

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 2 Fasting plasma insulin (µU/ml) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 3 Plasma glucose rate of disappearance (mg/kg/min) at cycle 6.
Figures and Tables -
Analysis 25.3

Comparison 25 Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg, Outcome 3 Plasma glucose rate of disappearance (mg/kg/min) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 1 Fasting serum glucose (mmol/L) at cycle 9.
Figures and Tables -
Analysis 26.1

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 1 Fasting serum glucose (mmol/L) at cycle 9.

Navigate to figure in ReviewOpen in new tab

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 2 Serum glucose 2‐h response (mmol/L) at cycle 9.
Figures and Tables -
Analysis 26.2

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 2 Serum glucose 2‐h response (mmol/L) at cycle 9.

Navigate to figure in ReviewOpen in new tab

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 3 Abnormal fasting serum glucose at cycle 9.
Figures and Tables -
Analysis 26.3

Comparison 26 Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg, Outcome 3 Abnormal fasting serum glucose at cycle 9.

Navigate to figure in ReviewOpen in new tab

Comparison 27 Biphasic levonorgestrel 50‐125 µg + EE 50 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Blood glucose ("random") (mg/dl) at 12 months.
Figures and Tables -
Analysis 27.1

Comparison 27 Biphasic levonorgestrel 50‐125 µg + EE 50 µg versus levonorgestrel 150 µg + EE 30 µg, Outcome 1 Blood glucose ("random") (mg/dl) at 12 months.

Navigate to figure in ReviewOpen in new tab

Comparison 28 Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mmol/L) at cycle 6.
Figures and Tables -
Analysis 28.1

Comparison 28 Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 1 Fasting plasma glucose (mmol/L) at cycle 6.

Navigate to figure in ReviewOpen in new tab

Comparison 28 Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Fasting glycosylated hemoglobin (%) at cycle 6.
Figures and Tables -
Analysis 28.2

Comparison 28 Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg, Outcome 2 Fasting glycosylated hemoglobin (%) at cycle 6.

Navigate to figure in ReviewOpen in new tab
Comparison 1. Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting serum glucose (mg/dl) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

6.60 [2.41, 10.79]

2 Fasting serum insulin (µU/ml) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.70 [‐3.33, 1.93]

3 Glucose AUC (h x mg/dl) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐25.21, 25.21]

4 Insulin AUC (h x µU/ml) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐1.30 [‐31.87, 29.27]

5 Change in fasting glycosylated hemoglobin (%) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐0.45, 0.85]

6 Fasting blood glucose (mmol/L) at cycle 6 Show forest plot

1

49

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.22, 0.22]

7 Fasting blood insulin (µU/ml) at cycle 6 Show forest plot

1

49

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐2.41, 3.01]

8 Change in insulin AUC (µU/mL) by 6 months Show forest plot

1

20

Mean Difference (IV, Fixed, 95% CI)

‐0.69 [‐2.38, 1.00]
Figures and Tables -
Comparison 1. Desogestrel 150 µg + EE 20 µg versus desogestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 2. Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting serum glucose (mg/dl) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐1.70 [‐7.81, 4.41]

2 Fasting serum insulin (µU/ml) at cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.10 [‐2.80, 2.60]

3 Glucose AUC (h x mg/dl) in cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐23.40 [‐51.08, 4.28]

4 Insulin AUC (h x µU/ml) in cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐18.0 [‐49.41, 13.41]

5 Change in fasting glycosylated hemoglobin (%) in cycle 3 Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐0.85, 0.45]

6 Fasting blood glucose (mmol/l) at cycle 6 Show forest plot

2

72

Mean Difference (IV, Fixed, 95% CI)

0.20 [0.00, 0.41]

7 Fasting blood glucose (mmol/l) at cycle 12 Show forest plot

2

62

Mean Difference (IV, Fixed, 95% CI)

0.15 [‐0.08, 0.38]

8 Fasting blood glucose (mmol/l) at cycle 24 Show forest plot

1

17

Mean Difference (IV, Fixed, 95% CI)

‐0.40 [‐0.72, ‐0.08]

9 Glucose 2‐h response (mmol/l) at cycle 6 Show forest plot

1

52

Mean Difference (IV, Fixed, 95% CI)

‐0.01 [‐0.97, 0.95]

10 Glucose 2‐h response (mmol/l) at cycle 12 Show forest plot

1

44

Mean Difference (IV, Fixed, 95% CI)

1.08 [0.45, 1.71]
Figures and Tables -
Comparison 2. Desogestrel 150 µg + EE 30 µg versus levonorgestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 3. Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting blood glucose (mmol/L) at cycle 6 Show forest plot

1

118

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.15, 0.15]

2 Fasting blood insulin (mlU/L) at cycle 6 Show forest plot

1

118

Mean Difference (IV, Fixed, 95% CI)

‐0.40 [‐2.34, 1.54]

3 Fasting C‐peptide (pmol/L) at cycle 6 Show forest plot

1

118

Mean Difference (IV, Fixed, 95% CI)

‐0.04 [‐0.12, 0.04]

4 Glucose AUC (min x mmol/L) at cycle 6 Show forest plot

1

116

Mean Difference (IV, Fixed, 95% CI)

42.00 [‐26.35, 110.35]

5 Insulin AUC (min x mlU/L) at cycle 6 Show forest plot

1

116

Mean Difference (IV, Fixed, 95% CI)

‐327.00 [‐1807.37, 1153.37]

6 C‐peptide AUC (min x nmol/L) at cycle 6 Show forest plot

1

116

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐38.14, 36.14]
Figures and Tables -
Comparison 3. Desogestrel 150 µg + EE 20 µg versus gestodene 60 µg + EE 15 µg
Navigate to table in Review
Comparison 4. Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dL) after 6 cycles Show forest plot

2

57

Mean Difference (IV, Fixed, 95% CI)

0.34 [‐3.99, 4.67]

2 Fasting plasma insulin (µU/ml) after 6 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

‐0.80 [‐3.16, 1.56]

3 Fasting plasma insulin (mIU/ml) after 6 cycles Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

4.10 [‐0.57, 8.77]

4 Fasting C‐peptide (pmol/L) after 6 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

13.0 [‐45.80, 71.80]

5 Glucose AUC (h x g/L) after 6 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

‐0.21 [‐0.85, 0.43]

6 Insulin AUC (h x IU/ml) after 6 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

14.0 [‐76.09, 104.09]

7 C‐peptide AUC (h x pmol/L) after 6 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

‐89.0 [‐587.05, 409.05]

8 Fasting glucose (g/L) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.07, 0.03]

9 Fasting insulin (IU/ml) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐3.74, 1.74]

10 Fasting C‐peptide (pmol/L) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

4.0 [‐42.84, 50.84]

11 Glucose AUC (h x g/L) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

0.29 [‐0.93, 1.51]

12 Insulin AUC (h x IU/ml) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐80.75, 80.75]

13 C‐peptide AUC (h x pmol/L) after 13 cycles Show forest plot

1

31

Mean Difference (IV, Fixed, 95% CI)

494.00 [‐694.17, 1682.17]
Figures and Tables -
Comparison 4. Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 20 µg
Navigate to table in Review
Comparison 5. Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dL) after cycle 6 Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐6.24, 4.24]

2 Fasting plasma insulin (mIU/mL) after cycle 6 Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

4.20 [‐3.18, 11.58]
Figures and Tables -
Comparison 5. Desogestrel 150 µg + EE 20 µg versus gestodene 75 µg + EE 20 µg
Navigate to table in Review
Comparison 6. Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dL) after cycle 6 Show forest plot

1

25

Mean Difference (IV, Fixed, 95% CI)

‐1.70 [‐7.93, 4.53]

2 Fasting plasma insulin (mIU/mL) after cycle 6 Show forest plot

1

25

Mean Difference (IV, Fixed, 95% CI)

3.5 [‐1.88, 8.88]
Figures and Tables -
Comparison 6. Desogestrel 150 µg + EE 30 µg versus gestodene 75 µg + EE 30 µg
Navigate to table in Review
Comparison 7. Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Glucose AUC (mg/dl) at 6 months Show forest plot

1

25

Mean Difference (IV, Fixed, 95% CI)

‐14.90 [‐38.08, 8.28]

2 Insulin AUC at 6 months Show forest plot

1

25

Mean Difference (IV, Fixed, 95% CI)

‐16.30 [‐38.06, 5.46]
Figures and Tables -
Comparison 7. Desogestrel 150 µg + EE 30 µg versus desogestrel 125 µg + EE 50 µg
Navigate to table in Review
Comparison 8. Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Glucose AUC (mmol/L) at 6 months Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐1.49, 1.69]

2 Insulin AUC (pmol/L) at 6 months Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

7.70 [‐21.47, 36.87]

3 C‐peptide AUC (pmol/L) at 6 months Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

201.60 [‐615.19, 1018.39]
Figures and Tables -
Comparison 8. Desogestrel 150 µg + EE 20 µg versus chlormadinone acetete 2 mg + EE 30 µg
Navigate to table in Review
Comparison 9. Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Glucose AUC (mg/dl) at 6 months Show forest plot

1

27

Mean Difference (IV, Fixed, 95% CI)

‐9.90 [‐28.33, 8.53]

2 Insulin AUC at 6 months Show forest plot

1

27

Mean Difference (IV, Fixed, 95% CI)

4.0 [‐12.61, 20.61]

3 Fasting blood glucose (mmol/l) at cycle 6 Show forest plot

1

52

Mean Difference (IV, Fixed, 95% CI)

0.21 [‐0.04, 0.46]

4 Fasting blood glucose (mmol/l) at cycle 12 Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

0.12 [‐0.16, 0.40]

5 Glucose 2‐h response (mmol/l) at cycle 6 Show forest plot

1

52

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐1.11, 0.71]

6 Glucose 2‐h response (mmol/l) at cycle 12 Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

0.37 [‐0.41, 1.15]
Figures and Tables -
Comparison 9. Desogestrel 150 µg + EE 30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review
Comparison 10. Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Glucose AUC (mg/dl) at 6 months Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

5.0 [‐14.94, 24.94]

2 Insulin AUC at 6 months Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

20.30 [4.24, 36.36]
Figures and Tables -
Comparison 10. Desogestrel 125 µg + EE 50 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review
Comparison 11. Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in glucose (mg/dL) from fasting to 1 h after 400 kcal drink at cycle 6 Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

1.90 [‐8.07, 11.87]

2 Change in insulin (µU/ml) from fasting to 1 h after 400 kcal drink at cycle 6 Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

12.60 [‐1.27, 26.47]
Figures and Tables -
Comparison 11. Desogestrel 50‐100‐150 µg + EE 35‐30‐30 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review
Comparison 12. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in glucose AUC (mg/dL) by 6 months Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

‐2.37 [‐6.72, 1.98]

2 Change in insulin AUC (µU/mL) by 6 months Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

‐2.58 [‐6.63, 1.47]

3 Change in C‐peptide AUC (ng/mL) by 6 months Show forest plot

1

30

Mean Difference (IV, Fixed, 95% CI)

0.04 [‐1.76, 1.84]
Figures and Tables -
Comparison 12. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus desogestrel 150 µg + (EE 20 µg or EE 30 µg)
Navigate to table in Review
Comparison 13. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Glucose AUC (hr x mmol/L) at cycle 6 Show forest plot

1

69

Mean Difference (IV, Fixed, 95% CI)

‐0.06 [‐1.41, 1.29]

2 Insulin AUC (hr x pmol/L) at cycle 6 Show forest plot

1

65

Mean Difference (IV, Fixed, 95% CI)

‐204.51 [‐389.64, ‐19.38]

3 Fasting glycosylated hemoglobin (%) at cycle 6 Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

‐0.16 [‐0.33, 0.01]
Figures and Tables -
Comparison 13. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 14. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Impaired glucose tolerance at cycle 5 Show forest plot

1

42

Odds Ratio (M‐H, Fixed, 95% CI)

0.16 [0.01, 3.64]

2 Insulin sensitivity at cycle 5 Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

1.9 [‐5.92, 9.72]
Figures and Tables -
Comparison 14. Etonogestrel 120 µg + EE 15 µg (vaginal ring) versus levonorgestrel 100 µg + EE 20 µg
Navigate to table in Review
Comparison 15. Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mmol/L) at 12 months Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.24, 0.26]

2 Fasting plasma glucose at 24 months Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.24, 0.20]

3 Fasting plasma insulin (pmol/L) at 12 months Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

‐6.45 [‐37.68, 24.78]

4 Fasting plasma insulin (pmol/L) at 24 months Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

12.09 [‐4.17, 28.35]

5 Fasting glycosylated hemoglobin (%) at 12 months Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

‐0.03 [‐0.27, 0.21]

6 Fasting glycosylated hemoglobin (%) at 24 months Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.11, 0.37]

7 Glucose incremental AUC (min x mmol/L) at 12 months Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐79.44, 79.44]

8 Glucose incremental AUC (min x mmol/L) at 24 months Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

‐59.00 [‐143.87, 25.87]

9 Insulin incremental AUC (min x nmol/L) at 12 months Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

3.20 [‐11.69, 18.09]

10 Insulin incremental AUC (min x nmol/L) at 24 months Show forest plot

1

68

Mean Difference (IV, Fixed, 95% CI)

‐9.40 [‐28.91, 10.11]
Figures and Tables -
Comparison 15. Etonogestrel 68 mg (implant) versus levonorgestrel 216 mg (implant)
Navigate to table in Review
Comparison 16. Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in fasting blood insulin (mU/L) at cycle 7 Show forest plot

1

51

Mean Difference (IV, Fixed, 95% CI)

1.1 [‐0.77, 2.97]

2 Change in glucose AUC (h x mg/L) at cycle 7 Show forest plot

1

53

Mean Difference (IV, Fixed, 95% CI)

0.23 [‐1.12, 1.58]

3 Change in fasting C‐peptide (ng/mL) at cycle 7 Show forest plot

1

53

Mean Difference (IV, Fixed, 95% CI)

0.09 [‐0.17, 0.35]

4 Change in C‐peptide 2‐h response (ng/mL) at cycle 7 Show forest plot

1

53

Mean Difference (IV, Fixed, 95% CI)

0.76 [‐0.27, 1.79]
Figures and Tables -
Comparison 16. Drospirenone 3 mg + EE 20 µg versus desogestrel 150 µg + EE 20 µg
Navigate to table in Review
Comparison 17. Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in fasting plasma glucose (mg/dL) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

0.56 [‐5.29, 6.41]

2 Change in fasting plasma insulin (µU/mL) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

‐1.86 [‐4.72, 1.00]

3 Change in fasting C‐peptide (µmol/L) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

14.4 [‐83.00, 111.80]

4 Change in fasting free fatty acids (µEq/L) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

‐42.17 [‐194.32, 109.98]

5 Change in glucose AUC (h x mg/dL) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

6.5 [‐18.07, 31.07]

6 Change in insulin AUC (h x µU/mL) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

6.50 [‐29.37, 42.37]

7 Change in C‐peptide AUC (h x µmol/L) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

0.29 [‐0.60, 1.18]

8 Change in free fatty acids AUC (h x µEq/L) by cycle 13 Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

‐91.3 [‐212.17, 29.57]
Figures and Tables -
Comparison 17. Drospirenone 3 mg + EE 30 µg versus desogestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 18. Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting serum glucose (mg/dL) at 12 months Show forest plot

1

58

Mean Difference (IV, Fixed, 95% CI)

‐1.30 [‐6.01, 3.41]

2 Change in fasting blood glucose (mg/dL) at 12 months Show forest plot

1

470

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.12, 0.12]

3 Glucose 2‐h response (mg/dL) at 12 months Show forest plot

1

58

Mean Difference (IV, Fixed, 95% CI)

6.5 [‐4.75, 17.75]

4 Change in glucose 2‐h response (mg/dL) at 12 months Show forest plot

1

470

Mean Difference (IV, Fixed, 95% CI)

‐0.30 [‐0.54, ‐0.06]
Figures and Tables -
Comparison 18. Norethisterone 1000 µg + EE 35 µg versus levonorgestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 19. Norethisterone 350 µg versus levonorgestrel 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mmol/L) at 6 months Show forest plot

1

33

Mean Difference (IV, Fixed, 95% CI)

‐0.62 [‐1.26, 0.02]

2 Fasting glycosylated hemoglobin (%) at 6 months Show forest plot

1

33

Mean Difference (IV, Fixed, 95% CI)

0.09 [‐0.66, 0.84]

3 Abnormal fasting plasma glucose at 6 months Show forest plot

1

33

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.07 [0.00, 1.30]

4 Abnormal fasting glycosylated hemoglobin at 6 months Show forest plot

1

33

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.97 [0.14, 6.61]
Figures and Tables -
Comparison 19. Norethisterone 350 µg versus levonorgestrel 30 µg
Navigate to table in Review
Comparison 20. Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 100 µg + EE 20 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Change in glucose (mmol/L) from baseline to cycle 4 Show forest plot

1

235

Mean Difference (IV, Fixed, 95% CI)

‐0.04 [‐0.28, 0.20]
Figures and Tables -
Comparison 20. Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 100 µg + EE 20 µg
Navigate to table in Review
Comparison 21. Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dl) at cycle 6 Show forest plot

2

144

Mean Difference (IV, Fixed, 95% CI)

‐0.88 [‐2.83, 1.06]

2 Fasting plasma glucose (mg/dl) at cycle 12 Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐5.38, 3.38]

3 Fasting plasma insulin (µg/dl) at cycle 6 Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

‐0.79 [‐4.31, 2.73]

4 Fasting plasma insulin (µU/ml) at cycle 6 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐4.77, 0.77]

5 Fasting plasma insulin (µU/ml) at cycle 12 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

1.0 [‐1.77, 3.77]

6 Glucose AUC (h x mg/dl) at cycle 6 Show forest plot

2

144

Mean Difference (IV, Fixed, 95% CI)

‐10.83 [‐29.62, 7.96]

7 Glucose AUC (h x mg/dl) at cycle 12 Show forest plot

1

57

Mean Difference (IV, Fixed, 95% CI)

‐14.0 [‐44.99, 16.99]

8 Insulin AUC (h x µg/dl) at cycle 6 Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

‐12.0 [‐58.88, 34.88]

9 Insulin AUC (h x µU/mL) at cycle 6 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

3.00 [‐33.46, 39.46]

10 Insulin AUC (h x µU/mL) at cycle 12 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

21.0 [‐15.46, 57.46]
Figures and Tables -
Comparison 21. Norethindrone 500‐750‐1000 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review
Comparison 22. Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dl) at cycle 6 Show forest plot

1

88

Mean Difference (IV, Fixed, 95% CI)

‐0.60 [‐3.32, 2.12]

2 Glucose AUC (h x µg/dl) at cycle 6 Show forest plot

1

88

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐27.51, 23.51]

3 Fasting plasma insulin (µg/dl) at cycle 6 Show forest plot

1

91

Mean Difference (IV, Fixed, 95% CI)

‐0.34 [‐3.66, 2.98]

4 Insulin AUC (h x µg/dl) at cycle 6 Show forest plot

1

91

Mean Difference (IV, Fixed, 95% CI)

‐10.0 [‐55.87, 35.87]
Figures and Tables -
Comparison 22. Norethindrone 500‐1000‐500 µg + EE 35 µg versus levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review
Comparison 23. Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dl) at cycle 6 Show forest plot

1

85

Mean Difference (IV, Fixed, 95% CI)

1.14 [‐1.74, 4.02]

2 Fasting plasma insulin (µg/dl) at cycle 6 Show forest plot

1

90

Mean Difference (IV, Fixed, 95% CI)

0.45 [‐2.63, 3.53]

3 Glucose AUC (h x µg/dl) at cycle 6 Show forest plot

1

85

Mean Difference (IV, Fixed, 95% CI)

8.0 [‐17.31, 33.31]

4 Insulin AUC (h x µg/dl) at cycle 6 Show forest plot

1

90

Mean Difference (IV, Fixed, 95% CI)

2.0 [‐35.64, 39.64]
Figures and Tables -
Comparison 23. Norethindrone 500‐1000‐500 µg + EE 35 µg versus norethindrone 500‐750‐1000 µg + EE 35 µg
Navigate to table in Review
Comparison 24. Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting serum glucose (mg/dl) after 12 months Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

10.05 [3.16, 16.94]

2 Glucose 2‐hr response (mg/dl) after 12 months Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

17.0 [5.67, 28.33]

3 Fasting serum insulin (nU/ml) after 12 months Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

3.40 [2.07, 4.73]

4 Insulin 2‐hr response (nU/ml) after 12 months Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

20.0 [‐47.41, 87.41]
Figures and Tables -
Comparison 24. Depot medroxyprogesterone acetate 150 mg versus norethisterone enanthate 200 mg
Navigate to table in Review
Comparison 25. Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mg/dl) at cycle 6 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

0.60 [‐2.33, 3.53]

2 Fasting plasma insulin (µU/ml) at cycle 6 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

0.28 [‐0.84, 1.40]

3 Plasma glucose rate of disappearance (mg/kg/min) at cycle 6 Show forest plot

1

48

Mean Difference (IV, Fixed, 95% CI)

0.11 [‐0.19, 0.41]
Figures and Tables -
Comparison 25. Norethisterone enanthate 50 mg + EV 5 mg (injected) versus norethisterone 500‐750‐1000 µg + EE 35 µg
Navigate to table in Review
Comparison 26. Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting serum glucose (mmol/L) at cycle 9 Show forest plot

1

298

Mean Difference (IV, Fixed, 95% CI)

0.07 [‐0.06, 0.20]

2 Serum glucose 2‐h response (mmol/L) at cycle 9 Show forest plot

1

298

Mean Difference (IV, Fixed, 95% CI)

0.14 [‐0.06, 0.34]

3 Abnormal fasting serum glucose at cycle 9 Show forest plot

1

298

Odds Ratio (M‐H, Fixed, 95% CI)

0.93 [0.06, 15.08]
Figures and Tables -
Comparison 26. Norethisterone enanthate 50 mg + EV 5 mg versus medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg
Navigate to table in Review
Comparison 27. Biphasic levonorgestrel 50‐125 µg + EE 50 µg versus levonorgestrel 150 µg + EE 30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Blood glucose ("random") (mg/dl) at 12 months Show forest plot

1

54

Mean Difference (IV, Fixed, 95% CI)

‐0.90 [‐8.61, 6.81]
Figures and Tables -
Comparison 27. Biphasic levonorgestrel 50‐125 µg + EE 50 µg versus levonorgestrel 150 µg + EE 30 µg
Navigate to table in Review
Comparison 28. Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Fasting plasma glucose (mmol/L) at cycle 6 Show forest plot

1

38

Mean Difference (IV, Fixed, 95% CI)

0.10 [‐0.18, 0.38]

2 Fasting glycosylated hemoglobin (%) at cycle 6 Show forest plot

1

38

Mean Difference (IV, Fixed, 95% CI)

‐0.30 [‐0.85, 0.25]
Figures and Tables -
Comparison 28. Gestodene 50‐70‐100 µg + EE 30‐40‐30 µg levonorgestrel 50‐75‐125 µg + EE 30‐40‐30 µg
Navigate to table in Review